New hope for myelofibrosis anemia: experimental drug enters human trials
NCT ID NCT04455841
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests an experimental drug called INCB000928, given alone or with the standard drug ruxolitinib, for people with myelofibrosis who have severe anemia or need regular blood transfusions. The main goals are to check the drug's safety, find the right dose, and see if it can improve red blood cell counts. About 84 participants are being studied to determine if this approach can help manage anemia without curing the underlying disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Azienda Ospedaliera Papa Giovanni Xxiii
Bergamo, 24127, Italy
-
Azienda Ospedaliera Universitaria San Luigi Gonzaga Orbassano
Orbassano, 10043, Italy
-
Azienda Ospedaliero-Universitaria Careggi (Aouc)
Florence, 50134, Italy
-
Centre Hospitalier D'Angers
Angers, 49033, France
-
Chiba Cancer Center
Chiba, 260-8717, Japan
-
City of Hope National Medical Center
Duarte, California, 91010, United States
-
City of Hope Orange County
Irvine, California, 92618, United States
-
Comitato Di Bioetica Della Fondazione Irccs Policlinico San Matteo
Pavia, 27100, Italy
-
Duke University Medical Center, Department of Hematologic Malignancies and Cellular Therapy
Durham, North Carolina, 27705, United States
-
Emory University - Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
Emory University-Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
Gifu Municipal Hospital
Gifu, 500-8513, Japan
-
Hospital Saint Louis
Paris, 75010, France
-
Institut Paoli Calmettes
Marseille, 13273, France
-
Kansai Medical University Hospital
Hirakata, 573-1191, Japan
-
Kumamoto Shinto General Hospital
Kumamoto, 862-8655, Japan
-
Lincoln County Hospital
Lincoln, LN2 5QY, United Kingdom
-
McGill University Jewish General Hospital
Montreal, Quebec, H3T1E2, Canada
-
Md Anderson Cancer Center
Houston, Texas, 77030, United States
-
Osaka International Cancer Institute
Osaka, 541-8567, Japan
-
Ospedale Santa Maria Della Misericordia Perugia
Perugia, 06124, Italy
-
Prebys Cancer Center
San Diego, California, 92103, United States
-
Princess Margaret Cancer Center
Toronto, Ontario, M5G 2M9, Canada
-
Royal Cornwall Hospital Truro Sunrise Centre
Truro, TR1 3LJ, United Kingdom
-
S Orsolas University Hospital Seragnoli Institute of Hematology
Bologna, 40138, Italy
-
Stanford Cancer Center
Palo Alto, California, 94304, United States
-
Start Midwest
Grand Rapids, Michigan, 49546, United States
-
Tokyo Medical and Dental University Hospital
Bunkyō City, 113-8519, Japan
-
United Lincolnshire Hospitals
Boston, PE21 9QS, United Kingdom
-
University Hospital of Wales
Cardiff, WLS, CF14 4XW, United Kingdom
-
Usc Norris Comprehensive Cancer Center
Los Angeles, California, 90089, United States
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
-
Weill Cornell Medical Centers
New York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can less be more? testing transfusion limits in ECMO
- A simple blood test trend may flag ICU patients at risk
- Rethinking anemia: does blood hemoglobin tell the whole story?
- Can a new daily pill shrink the spleen and ease myelofibrosis symptoms?
- A simple nutrient may shield Babies' brains from iron deficiency
- School health rooms and trained teachers: a new hope for Zambia's children?